Recurrence of infectious virus from the latent viral genomes is the initiating event in the pathogenesis of cytomegalovirus (CMV) disease during states of immunodeficiency. Interstitial pneumonia is a frequent manifestation of posttransplantation CMV disease, in particular after bone marrow transplantation and heart and lung transplantations. Recurrence Cytomegaloviruses (CMV) are members of the betaherpesviruses (29). It is a common feature of herpesviruses that acute infection is not terminated by clearance of infectious virus and the viral genome but is followed by a phase of persistent virus replication that can vary largely in duration and is often confined to a particular tissue site. Eventually, virus is retained in a latent state defined operationally by the inability to detect infectious particles and by the possibility of inducing a recurrent infection (30).
as well as within latently infected organs of the transplant recipient. The reason for a predilection of the lungs as a site of CMV pathology is so far unknown. In a murine model of CMV latency, the lungs were identified as an authentic site of latent infection, since the viral genome remained detectable in lung tissue even after it was cleared to an undetectable level in blood and bone marrow. A comparison between the lungs and the spleen, the previously most thoroughly investigated site of murine CMV latency, revealed a 10-fold-higher burden of latent viral genome for the lungs. Most important, the organ-specific risk of in vivo recurrence was found to correlate with the organ-specific viral genomic load. This new finding thus characterizes the lungs as a high-risk organ for CMV recurrence, and this fact may explain in part why interstitial pneumonia is a frequent manifestation of recurrent CMV infection.
Cytomegaloviruses (CMV) are members of the betaherpesviruses (29) . It is a common feature of herpesviruses that acute infection is not terminated by clearance of infectious virus and the viral genome but is followed by a phase of persistent virus replication that can vary largely in duration and is often confined to a particular tissue site. Eventually, virus is retained in a latent state defined operationally by the inability to detect infectious particles and by the possibility of inducing a recurrent infection (30) .
Human CMV is highly prevalent in the population. It does not cause overt disease in immunocompetent hosts, but immunocompromised patients are at risk of severe and often fatal manifestations of CMV disease (38) . Specifically, primary infection during pregnancy is responsible for birth defects (3) , CMV contributes to the syndrome in the terminal stages of AIDS (11) , and CMV recurrence is the major viral complication in bone marrow transplantation (9, 23) as well as in organ transplantation, including liver, kidney, and heart and lung transplantations (12) . It is established that recurrence within the transplantation recipient as well as from the transplant both contribute to the overall risk of CMV disease. Collectively, the clinical data indicate that a variety of organs, and in particular also cells in blood and bone marrow (28, 34, 37) , can serve as a source of latent CMV.
Murine models of CMV latency have been employed to address specific questions experimentally (reviewed in reference 16) . The interest was focused on the spleen as a site of murine CMV latency, and recent work has pointed to the sinusoidal lining cell of the splenic stroma as a candidate for the cell type that may harbor the latent genome (21, 26) . However, studies of transmission by transplantation (10, 31) , recurrence in splenectomized mice (16) (7, 39) , and amplification of the viral genome (18) have suggested various other organs as additional sources for latent virus. Collectively, data in the model revealed a good fit to human CMV with respect to organ sources of latent virus. This finding has led to the belief that multiple organs are true sites of CMV latency. However, the apparent possibility that contamination by latently infected circulating or temporarily tissue-residing blood-borne cells may account for the multiple organ transmission was never controlled for rigorously. To date, the lungs have not been taken into consideration as an organ site of CMV latency, even though interstitial pneumonia is a significant manifestation of CMV disease both in patients (23) and in murine models (15, 27, 35) .
In this report, the lungs are identified as an authentic site of murine CMV latency by the detection of a high-copy density of viral DNA in lung tissue at a stage of latent infection at which the viral genome in blood had fallen below the detection level. The incidence of experimentally induced in vivo recurrence in the lungs and spleen correlated with the tissue burden of the latent viral genome, which was found to be 10-fold higher in the lungs. The high risk of recurrence in the lungs offers an explanation for the high incidence of interstitial pneumonia among the diverse manifestations of CMV disease.
MATERIALS AND METHODS
Virus and infection conditions. Experiments were performed with the original Smith strain (36) of mouse CMV distributed by the American Type Culture Collection under the product number ATCC VR-194, for which the physical map was determined by Ebeling et al. (8) . The virus was propagated in mouse embryo fibroblast culture and partially purified by sedimentation through a 15% sucrose cushion to preclude the unspecific toxic effects that are associated with virus preparations obtained from salivary glands (6 Sensitivity and semiquantitative evaluation of the PCR. Samples with all ingredients except template DNA served as the negative control. To determine the sensitivity of the PCR, defined copy numbers of plasmid pIE111 were mixed with 3 ,g of certified negative chromosomal mouse DNA from organs of uninfected mice. The circular plasmid pIE111 encompasses genes iel and ie3 of murine CMV (22) . Linearization of the plasmid did not change the sensitivity of detection. The PCR products were quantitated by densitometric scanning and computing from the autoradiographs with a Joyce-Loebl scanner. It was not intended in our experiments to determine precise copy numbers of viral DNA in host tissues but rather to rank test signals as <10, 10, 100, or >100 copies.
RESULTS
Protocol for establishing latent infection. Human CMV is acquired mainly perinatally and during early childhood. Accordingly, previous murine models of CMV latency were based on experimental infection of neonates or of weanling mice (reviewed in reference 16). We used here the model of neonatal infection. BALB/c mice were infected intraperitoneally with 102 PFU of purified mouse CMV at the first day after birth; the mice were referred to as latency-type N mice. BALB/c is a mouse strain that is genetically susceptible to infection with mouse CMV (33), and, according to our experience, the Smith strain is highly virulent in BALB/c newborns even when purified from cell culture. Thus, mortality was 40% on average, with death occurring typically in the third week. Survivors showed runting until 4 to 6 weeks after infection, recovered, and appeared phenotypically normal later on. By the time of death, virus had replicated in a variety of vital organs, whereas, in the survivors, virus replication was confined to the salivary glands at 1 month after infection. Restricted to that specific site, persistent infection continued for about 4 months before it declined, and, beyond 6 months postinfection, virus was no longer detectable in homogenates of salivary glands, lungs, and spleen. Specifically, no virus was detected at 1 year postinfection in any of these organs in a total of 40 neonatally infected mice tested (Table 1) when the most sensitive technique was employed, namely, the in vitro plaque assay with centrifugal enhancement of infectivity (13) . To Fig. 1 ) within cellular DNA of different organ sources, graded numbers of the iel-containing plasmid pIE111 were titrated to a constant amount of cellular DNA from normal lungs or spleen and a 363-bp sequence from exon 4 of gene iel was amplified in 35 cycles (Fig. 2) . The endpoint titration revealed a clearly visible autoradiographic signal with 10 copies of the plasmid and a faint signal with a single copy (Fig. 2, top) . The sensitivity was independent of the organ source of the carrier DNA, lung DNA or spleen DNA (Fig. 2, left Densitometric scanning of the autoradiographs (Fig. 2,  center) and computing of the signal volumes revealed a nonlinear relationship between plasmid copy numbers and the amount of PCR product in a log-log plot (Fig. 2, bottom) . The relationship is linear only between 10 and 100 copies, as is indicated by the finding that 1 log change on the abscissa results in 1 log change on the ordinate. Therefore, 10 and 100 copies of pIE111 were routinely used as positive controls in the subsequent experiments.
Delayed clearance of the viral genome from the blood. There is preliminary evidence that multiple organs harbor latent CMV (reviewed in references 16 and 24). However, one must envisage the possibility that the latently infected cell is not intrinsic to a particular tissue but is just a passenger. This objection is particularly relevant, since blood-borne cells are a known source of latent CMV (2, 25) . While perfusion of organs may more or less quantitatively remove cells migrating in blood vessels (10), blood-borne cells temporarily residing in tissues are difficult to exclude formally, except if organs are positive for the viral genome at a stage of latency at which the viral DNA is cleared from the blood.
We have therefore tracked the presence of viral DNA in blood leukocytes at different times after termination of viral replication in organs by PCR amplification of the 363-bp test sequence from gene iel (Fig. 3) . At each time point, blood leukocytes were pooled from five mice scored individually to have cleared infectious virus from salivary glands, lungs, and spleen. The frequency of leukocytes carrying viral DNA was estimated by endpoint titration of the cells. At 6 months postinfection, that is, shortly after termination of virus persistence in the salivary glands, ca. 10 to 100 copies of the viral sequence were detected in the DNA from 104 leukocytes, whereas no signal was obtained from 103 leukocytes (Fig. 3, top) . The minimum estimate for the frequency of positive cells is therefore 10-4. At a later stage, at 1 year postinfection, corresponding to 6 months after cessation of virus replication, the viral genome was still detectable, although in a 100-fold-lower frequency of leukocytes (Fig. 3,  bottom) postinfection (Fig. 4) . In this particular experiment, the plasmid controls were made with blood leukocyte DNA and bone marrow cell DNA derived from mouse Ni as the carrier DNA to ensure that amplification was not inhibited by factors in the DNA preparation. In three of four animals (Fig. 4 , Ni to N3), no viral DNA was detected in two independent 3-,g samples of leukocyte or bone marrow cell DNA, while individual N4, even though it was also negative for infectious virus in organs, was positive as indicated by both blood samples, with ca. 100 copies per sample (Fig. 4,  N4) . Mouse N4 was therefore excluded from the analysis of latent viral DNA in organs. It should be noted that the two samples represented 50% of the yield of DNA from the blood of mice at 1 year of age. From this result and the assay sensitivity, it can be calculated that the total copy number in the blood of mice Ni to N3 was <20 copies. The virtual absence of viral DNA in the blood provided additional evidence against a low-level persistent infection in individuals Ni to N3, as persistent infection should have resulted in continued delivery of viral DNA to the blood.
The lungs and spleen are authentic sites of murine CMV latency. Since a significant contamination of organs by latently infected blood leukocytes was excluded for mice Ni to N3 at 1 year postinfection (Fig. 4) , these mice served to answer the principal question of intrinsic CMV latency in organs independent of blood-borne passengers. Previous investigators have noted that the latent CMV genome in the spleen is not detectable by in situ cytohybridization (21, 26) or by Southern blotting without prior amplification (18) . Therefore, as described for the blood, amplification by PCR of the iel gene test sequence was employed to detect viral DNA in organs. We focused on the comparison between the lungs and spleen. The lungs were chosen because of their relevance in viral pathology, and the spleen was chosen because it was considered a major site of murine CMV latency on the basis of in vitro virus recurrence from explant cultures (reviewed in reference 16). Both organs clearly harbored latent CMV DNA (Fig. 5) . In the lungs, there was almost no variance among individuals and also no apparent sample variance. All three individuals tested showed a viral sequence copy number of > 100 in each of six independently amplified 3-,ug samples of tissue DNA (Fig. 5, left) sample, and in the case of mouse Ni not all samples were positive. It should be noted that the viral sequence was also detected in salivary glands and adrenal glands (>100 copies per sample), the heart (ca. 100 copies), and the kidneys (510 copies) (unpublished data). If one considers only the lungs, a minimum of 600 copies was thus contained already within the tested 18 p,g of lung DNA, which can be extrapolated on the basis of the DNA yield to > 104 copies in the whole organ. As the blood of the same individuals contained <20 copies in total, this experiment proved the existence of multiple authentic organ sites of murine CMV latency. High load of the latent viral genome in the lungs. Because most previous studies have focused on the spleen as the major site of murine CMV latency, the apparently higher prevalence of viral DNA in the lungs came as a surprise and needed to be quantitated and controlled for more thoroughly. Endpoint titration starting with 3 p,g of tissue DNA from mouse N2 revealed 30 ng of lung DNA as the detection limit for the viral test sequence, whereas the detection limit was 300 ng with spleen DNA (Fig. 6) . Furthermore, this 10-fold difference was corroborated by the comparison of the signal intensities at any step in the titration.
It is critical to exclude the possibility that the apparent signal difference just reflects a technical difference in the amplification efficacies of lung and spleen DNA. As the physical state of the viral genome during latency is unknown, it is open to question whether it is circular, a state found as a replicative intermediate in productive infection (20) , or whether it is integrated into the cellular genome. Controls should account for both possibilities. That a circu- lar plasmid containing the test sequence, namely, plasmid pIE111, is amplified with the same efficacy from lung and spleen DNA has been documented above (recall Fig. 2 ). To account for the second possibility, a cellular gene sequence, a sequence from mouse P-actin (1) , was amplified from the same DNA preparations used for Fig. 6 for the detection of the CMV sequence (Fig. 7) . With a detection limit of 30 pg, the amplification efficacy for the cellular test gene was the same for lung and spleen DNA. This excluded an influence of the organ DNA source on the technical amplification efficacy. In conclusion, the lungs harbored approximately 10-fold more latent viral DNA relative to cellular DNA than did the spleen.
The lungs represent a major site of in vivo CMV recurrence.
The detection of a viral test sequence in tissue does not indicate whether the genome is complete and functional for reactivation and virus recurrence. The speculation that the regulatory gene iel may have been selectively retained in cells was refuted by amplification of another viral sequence belonging to gene el (data not shown). However, critical deletions in the genome are hereby not excluded, and testing more genes by PCR would add little to solve this principal problem. We have therefore determined organ-specific incidences of recurrence in vivo after general immunosuppression and ablation of hematopoiesis by total-body gamma irradiation (Table 1) . This suppression regimen is related to the hematoablative conditioning in clinical bone marrow transplantation, after which human CMV recurrence arises as a major problem. In two experiments with latently infected mice at 1 year after neonatal infection, no virus was detectable in lungs or spleen (or salivary glands; data not shown) when no treatment was given. The prevalence of prolonged persistence or the incidence of spontaneous recurrence was therefore <5% (0 of 20 mice) in each experiment. By contrast, taking both experiments together, the incidence of induced recurrence was 12.5% (5 of 40 mice) for In murine models of CMV latency in the spleen, approaches to localize the latent genome by cell separation followed by in vitro coculture reactivation (21) or by PCR (26) have not yet led to an unequivocal conclusion. A sinusoidal lining cell of the splenic stroma with an unusual phenotype, for which a counterpart has also been described for the human spleen stroma (4) , was identified in situ as a productively infected cell type during acute infection (21) , and the stroma was found to be enriched with the latent genome (21, 26 will be difficult to achieve.
While blood-borne circulating or temporarily homing cells were excluded as cellular sites of virus latency by our approach, long-term-resident, aged histiocytes must remain in the discussion. It may be speculated that differences in the homing patterns of histiocytes may account for the observed organ differences in the prevalence of latent viral DNA and risk of recurrence. However, recent work has provided evidence for macrophages serving as a source of CMV amplification and dissemination rather than being the cellular site of CMV latency and recurrence (14) . If the latently infected cell in the lungs is a sinusoidal lining cell or endothelial cell as proposed for the spleen, either this cell type(s) must be relatively more frequent in the lungs or a higher proportion of it was hit during the acute phase of infection.
Detection of a viral test sequence by PCR does not discriminate between latent infection with a functional genome and abortive infection with a defective genome. The in vivo recurrence is therefore of utmost importance, as it proves that at least a fraction of the detected viral genomes were functional. Interestingly, the risks of recurrence in lungs and spleen correlated with the number of detected viral copies in these two organs.
A promising conclusion from our data is that the murine model of CMV infection and latency is closer to the pathogenesis of human CMV than was previously thought. As a consequence, the focus of interest should be redirected from the spleen to the lungs, the most critical site of human CMV pathology during recurrent infection of immunocompromised patients. The recurrence of virus is most probably not the only parameter in the pathogenesis of interstitial CMV pneumonia (reviewed in references 9 and 35), but it is undoubtedly the prime event. Thus, the finding that the lungs represent a high-risk organ for CMV latency and recurrence adds to the understanding of CMV pneumonia.
